title: PDE-5 inhibitors lower portal and pulmonary pressure in portopulmonary hypertension.
authors.forename: P
authors.initials: P
authors.lastname: Deibert
authors.forename: H
authors.initials: H
authors.lastname: Bremer
authors.forename: M
authors.initials: M
authors.lastname: Roessle
authors.forename: A-K
authors.initials: AK
authors.lastname: Kurz-Schmieg
authors.forename: W
authors.initials: W
authors.lastname: Kreisel
mesh_terms: D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000037:antagonists & inhibitors; D002243:Carbolines / Q000627:therapeutic use*; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D006801:Humans; D006975:Hypertension, Portal / Q000188:drug therapy*; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D000068581:Tadalafil
chemical_list: D002243:Carbolines; D010726:Phosphodiesterase Inhibitors; D000068581:Tadalafil; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; C517381:PDE5A protein, human